224 related articles for article (PubMed ID: 18299336)
1. Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.
Kitamura Y; Koto H; Matsuura S; Kawabata T; Tsuchiya H; Kusuhara H; Tsujimoto H; Sugiyama Y
Drug Metab Dispos; 2008 May; 36(5):807-10. PubMed ID: 18299336
[TBL] [Abstract][Full Text] [Related]
2. Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.
Mealey KL; Waiting D; Raunig DL; Schmidt KR; Nelson FR
J Vet Pharmacol Ther; 2010 Oct; 33(5):453-60. PubMed ID: 20840389
[TBL] [Abstract][Full Text] [Related]
3. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
4. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
Kharasch ED; Hoffer C; Altuntas TG; Whittington D
J Clin Pharmacol; 2004 Mar; 44(3):224-33. PubMed ID: 14973303
[TBL] [Abstract][Full Text] [Related]
5. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
6. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.
Pauli-Magnus C; Feiner J; Brett C; Lin E; Kroetz DL
Clin Pharmacol Ther; 2003 Nov; 74(5):487-98. PubMed ID: 14586389
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
[TBL] [Abstract][Full Text] [Related]
9. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
[TBL] [Abstract][Full Text] [Related]
10. Influence of P-glycoprotein on the disposition of fexofenadine and its enantiomers.
Li F; Howard KD; Myers MJ
J Pharm Pharmacol; 2017 Mar; 69(3):274-284. PubMed ID: 28090646
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
12. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
[TBL] [Abstract][Full Text] [Related]
13. Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Kataoka M; Yokoyama T; Masaoka Y; Sakuma S; Yamashita S
Eur J Pharm Sci; 2011 Nov; 44(4):544-51. PubMed ID: 21963456
[TBL] [Abstract][Full Text] [Related]
14. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
Uno T; Shimizu M; Sugawara K; Tateishi T
Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
[TBL] [Abstract][Full Text] [Related]
15. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
Yamazaki A; Kumagai Y; Yamane N; Tozuka Z; Sugiyama Y; Fujita T; Yokota S; Maeda M
J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
[TBL] [Abstract][Full Text] [Related]
16. Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe.
Zhou Q; Ye Z; Ruan Z; Zeng S
J Ethnopharmacol; 2013 Apr; 146(3):744-9. PubMed ID: 23422332
[TBL] [Abstract][Full Text] [Related]
17. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
[TBL] [Abstract][Full Text] [Related]
18. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
Jin MJ; Han HK
J Food Sci; 2010 Apr; 75(3):H93-6. PubMed ID: 20492299
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
Miura M; Uno T; Tateishi T; Suzuki T
Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498
[TBL] [Abstract][Full Text] [Related]
20. The effect of rifampin administration on the disposition of fexofenadine.
Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
